Troutman Sanders Client Indivior Prevails In Patent Suit
ATLANTA – July 12, 2016 – Troutman Sanders served as trial counsel to specialty pharmaceutical company Indivior in litigation involving Orange Book-listed patents covering Indivior’s blockbuster Suboxone ® Film treatment for opioid dependence.
Following a bench trial, Judge Richard Andrews of the U.S. District Court for the District of Delaware ruled against defendants Actavis Laboratories, Inc., Par Pharmaceutical, Inc. and IntelGenx Technologies Corp. with respect to the defendants’ filing of respective Abbreviated New Drug Applications (“ANDAs”) seeking authorization to market generic versions of Suboxone ® Film. The Court held that one of the Orange Book-listed patents, U.S. Patent No. 8,603,514, is valid and would be infringed by defendants’ proposed generic products. This ruling will bar the U.S. Food & Drug Administration from approving defendants’ ANDAs prior to the expiration of the ’514 patent in April 2024.
This decision bolstered recent decisions by the Patent Trial and Appeal Board that a patent related to the ’514 patent was valid and refusing to institute inter partes review proceedings requested by Teva Pharmaceuticals.
Related cases involving the Orange Book-listed patents against four other generic defendants remain pending.
The Troutman Sanders trial and litigation team includes Dan Ladow, Charan Brahma, Jim Bollinger, Tim Heaton, Rob Browne, Magnus Essunger, Suja Vathyam, Bennet Moskowitz, Dan Sharpe, Katherine Harihar, Andrew Regan, Dustin Weeks, Puja Lea, Lindsay Henner, EA Weeks, Matthew Hu, Martha Matos and Molly Olson.
About Troutman Sanders
With a diverse practice mix, workforce and footprint, Troutman Sanders has cultivated its reputation for a higher commitment to client care for over 120 years. Ideally positioned to help clients across sectors realize their business
goals, the firm’s 650 attorneys transact for growth, resolve mission-threatening disputes and navigate complex legal and regulatory challenges. See
troutman.com for more information.
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is
the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized
and treated chronic disease. Building on its robust, global portfolio of opioid dependence treatments featuring SUBOXONE
® (buprenorphine and naloxone) Sublingual Film (CIII), SUBOXONE
® (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX
® (buprenorphine) Sublingual Tablet, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-morbidities of addiction including
alcohol use disorder, cocaine intoxication and schizophrenia. Headquartered in the United States in Richmond, Va., Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries
worldwide. Visit www.Indivior.com to learn more.